Shares of Healthcare sector company Mirati Therapeutics moved -7.4% today, and are now trading at a price of $89.16. The mid-cap stock's daily volume was 455,945 compared to its average volume of 1,035,371. The S&P 500 index returned a -1.4% performance.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is based in San Diego and has 413 full time employees. Its market capitalization is $5,134,448,128.
16 analysts are following Mirati Therapeutics and have set target prices ranging from $72 to $188 per share. On average, they have given the company a rating of buy. At today's prices, MRTX is trading -22.93% away from its average analyst target price of $115.69 per share.
Over the last year, MRTX shares have gone down by -27.1%, which represents a difference of -15.8% when compared to the S&P 500. The stock's 52 week high is $154.17 per share and its 52 week low is $32.96. Mirati Therapeutics has averaged free cash flows of $-223,497,250.0 over the last four years, with a mean growth rate of -80.6%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.